Evoke Pharma (NASDAQ: EVOK) reported Q3 EPS of ($0.34), $0.14 worse than the analyst estimate of ($0.20).

As of September 30, 2017, our cash and cash equivalents were approximately $10.4 million.

For earnings history and earnings-related data on Evoke Pharma (EVOK) click here.